Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue:        
Grant and contract revenue $ 849,732 $ 6,439 $ 2,344,777 $ 1,049,988
Operating expenses:        
Research and development 3,172,663 3,129,356 8,745,966 9,725,744
General and administrative 6,579,193 1,993,136 11,651,415 7,201,196
Goodwill impairment loss 0 737,000 0 737,000
Change in fair value of contingent consideration 229,000 502,000 1,045,000 728,290
Total operating expenses 9,980,856 6,361,492 21,442,381 18,392,230
Loss from operations (9,131,124) (6,355,053) (19,097,604) (17,342,242)
Change in fair value of warrant liability (37,230)   (1,039,303)  
Investor relations expense     (66,767)  
Interest income 140,614 97,415 249,404 373,060
Other income (expense), net 111,307 (73,275) 127,599 (80,539)
Total non-operating income (loss) 214,691 24,140 (729,067) 292,521
Net loss before income taxes (8,916,433) (6,330,913) (19,826,671) (17,049,721)
Income tax expense       (45,178)
Net loss (8,916,433) (6,330,913) (19,826,671) (17,094,899)
Net loss - non-controlling interest (64,824) (136,315) (228,526) (413,955)
Net loss attributable to Heat Biologics, Inc. $ (8,851,609) $ (6,194,598) $ (19,598,145) $ (16,680,944)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.06) $ (0.18) $ (0.20) $ (0.50)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 143,728,870 33,650,829 96,481,271 33,255,535
Comprehensive loss        
Net loss $ (8,916,433) $ (6,330,913) $ (19,826,671) $ (17,094,899)
Unrealized (loss) gain on foreign currency translation (63,954) 63,711 (24,660) 72,134
Total comprehensive loss (8,980,387) (6,267,202) (19,851,331) (17,022,765)
Comprehensive loss attributable to non-controlling interest (64,824) (136,315) (228,526) (413,955)
Comprehensive loss - Heat Biologics, Inc. $ (8,915,563) $ (6,130,887) $ (19,622,805) $ (16,608,810)